期刊
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
卷 40, 期 1, 页码 -出版社
BMC
DOI: 10.1186/s13046-021-01865-2
关键词
Head and neck cancer; miR-34a; Aneuploidy; P53; MET; micoRNA
类别
资金
- Columbia University Irving Medical Center [UL1 TR001873]
- Columbia University College of Dental Medicine [UL1 TR001873]
- Irving Institute for Clinical and Translational Research [UL1 TR001873]
- NIH/NIDCR [DE029546-01]
- American Association of Cancer Research [20-60-51-MOME]
- Mark Foundation for Cancer Research [20-60-51-MOME]
- NIH [P30 CA013696]
miR-34a directly targets MET and acts as a tumor suppressor in HNSCC by inhibiting HNSCC cell proliferation. Administration of LNA-miR-34a reduces HNSCC cell proliferation and tumor burden, suppresses immunosuppressive effects in the tumor microenvironment, and increases the frequency of Th1 cells and CD8 naive T cells in HNSCC patient samples.
BackgroundMicroRNAs (miRs) have been shown to play an important role in tumorigenesis, including in head and neck squamous cell carcinoma (HNSCC). The miR-34 family is thought to play a role in tumor suppression, but the exact mechanism of their action in HNSCC is not well understood. Moreover, the impact of chromosomal changes and mutation status on miR-34a expression remains unknown.MethodsDifferential expression of miR-34a, MET, and genomic alterations were assessed in the Cancer Genome Atlas (TCGA) datasets as well as in primary HNSCC and adjacent normal tissue. The biological functions of miR-34a in HNSCC were investigated in samples derived from primary human tumors and HNSCC cell lines. The expression of MET was evaluated using immunohistochemistry, and the molecular interaction of miR-34a and MET were demonstrated by RNA pulldown, RNA immunoprecipitation, luciferase reporter assay, and rescue experiments. Lastly, locked nucleic acid (LNA) miRs in mouse xenograft models were used to evaluate the clinical relevance of miR-34a in HNSCC tumor growth and modulation of the tumor microenvironment in vivo.ResultsChromosome arm 1p loss and P53 mutations are both associated with lower levels of miR-34a. In HNSCC, miR-34a acts as a tumor suppressor and physically interacts with and functionally targets the proto-oncogene MET. Our studies found that miR-34a suppresses HNSCC carcinogenesis, at least in part, by downregulating MET, consequently inhibiting HNSCC proliferation. Consistent with these findings, administration of LNA-miR-34a in an in vivo model of HNSCC leads to diminished HNSCC cell proliferation and tumor burden in vitro and in vivo, represses expression of genes involved in epithelial-mesenchymal transition, and negates the oncogenic effect of MET in mouse tumors. Consistently, LNA-miR-34a induced a decreased number of immunosuppressive PDL1-expressing tumor-associated macrophages in the tumor microenvironment. In HNSCC patient samples, higher levels of miR-34a are significantly associated with a higher frequency of Th1 cells and CD8 naive T cells.ConclusionsOur results demonstrate that miR-34a directly targets MET and maintains anti-tumor immune activity. We propose miR-34a as a potential new therapeutic approach for HNSCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据